Skip to search formSkip to main contentSkip to account menu

piroximone

Known as: 4-ethyl-1,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidazol-2-one 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Cardiotonic AgentsImidazolesPhosphodiesterase InhibitorsPlatelet Aggregation Inhibitors

Narrower (1)

MDL 19,205

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Review
1990
Review
1990
Pharmacokinetics and pharmacodynamics of phosphodiesterase-III inhibitors
Review
1989
Review
1989
Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase.
1989
1989
Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activities in rabbit ventricular myocardium: relations to post-natal maturation.
Highly Cited
1988
Highly Cited
1988
Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Highly Cited
1988
Highly Cited
1988
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction.
Highly Cited
1988
Highly Cited
1988
The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi.
Although many of the new cardiotonic agents are known to increase cAMP and to inhibit with variable potency a low Km cAMP… 
Highly Cited
1987
Highly Cited
1987
In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.
Several novel cardiotonic vasodilators including bipyridines (amrinone and milrinone), imidazolones (enoximone and piroximone… 
1986
1986
Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Piroximone (MDL 19,205), a new phosphodiesterase inhibitor with positive inotropic and vasodilating properties, was administered… 
Highly Cited
1985
Highly Cited
1985
The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret
1 The effects of milrinone and piroximone were compared to those of isoprenaline, dibutyryl adenosine 3′:5′‐cyclic monophosphate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)